

TRANSGENE BIOTEK LIMITED
68,69,&70, ANRICH INDUSTRIAL AREA
BOLLARAM, MEDAK DISTRICT

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2014

(Rs. in Lakhs)

	Particulars	Quarter ended 30.06.2014	Quarter ended 31.03.2014	Quarter ended 30.06.2013	For Previous year ended 31.03.2014
		Unaudited	Audited	Unaudited	Audited
1	(a) Net Sales/Income from Operations	10.52	28.25	23.89	98.11
	(b) Other Operating Income	-	-	-	-
	2. Expenditure				
	a. Increase/decrease in stock in trade and work in progress	-	0.00	7.02	14.75
	b. Consumption of raw materials	1.80	1.37	2.34	9.28
2	c. Purchase of traded goods	-	0.00	0	0.00
	d. Employees cost	24.33	72.21	10.47	102.43
	e. Depreciation	429.02	1,448.26	90.51	1721.55
	f. Other expenditure	26.60	36.22	27.89	128.57
	Total	481.81	1,558.25	138.23	1976.57
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	(471.29)	(1,530.00)	(114.34)	(1878.46)
4	Other Income	-	40.00	0.00	80.00
5	Profit / (loss) from Ordinary activities before finance cost and exceptional items(3+4)	(471.29)	(1,490.00)	(114.34)	(1798.46)
6	Finance Cost	0.07	0.05	0.02	0.05
7	Profit / (loss) from ordinary activities after finance cost but before Exceptional Items (5-6)	(471.36)	(1,490.05)	(114.36)	(1798.51)
8	Exceptional items*	-	-	0	0.00
9	Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)	(471.36)	(1,490.05)	(114.36)	(1798.51)
10	Tax expense	-	-	0.00	0.00
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	(471.36)	(1,490.05)	(114.36)	(1798.51)
12	Extraordinary Item (net of tax expense if any)	-	-	-	-
13	Net Profit(+)/ Loss(-) for the period (11-12)	(471.36)	(1,490.05)	(114.36)	(1798.51)
14	Share of profit/(loss) of associates	-	-	-	-
15	Minority Interest	-	-	-	-
16	Net Profit(+)/ Loss(-) after taxes, Minority interest and share of profit/(Loss) of associates (13-14-15)	(471.36)	(1,490.05)	(114.36)	(1798.51)
17	Paid-up equity share capital (Face value of share of Rs 10/- each)	7,577.00	7577.00	6,577.00	7,577.00
	No of Shares	75,770,000	75,770,000	65,770,000	75,770,000
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	23,669.46	24,045.64	26,621.92	24,045.64
	Earnings Per Share (EPS)				
19	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(0.62)	(1.97)	(0.17)	(2.37)
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(0.62)	(1.97)	(0.17)	(2.37)
20	Public Shareholding				
	No. of shares	59342098	59342098	59,342,098	59342098
	Percentage of shareholding	78.32	78.32	90.23	78.32
	Promoters and promoter group Shareholding **	16427902	16427902	6427902	16427902
	a) Pledged/Encumbered	0.00	0.00	0.00	0.00
	Number of shares	0.00	0.00	0.00	0.00
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00
21	Percentage of shares (as a% of the total share capital of the company)	0.00	0.00	0.00	0.00

[Signature]

b) Non-encumbered				
Number of Shares	16427902	16427902	6427902	16427902
Percentage of shares (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
Percentage of shares (as a % of the total share capital of the company)	21.68	21.68	9.77	21.68


Notes to the Results

- 1) The work on the new CGMP compliant manufacturing facility for the production of APIs is now completed and the scheduled production of APIs is underway.
- 2) With unacceptable delay in commencing the production of Tacrolimus, the management has decided to part with Cipan and scheduled its production too at the new facility.
- 3) As reported earlier, we continue to generate exciting data on our oral Insulin and oral delivery of protein drugs and this forms the basis for our ongoing discussions with the large pharma companies.
- 4) Like our oral delivery platform, our patented AAV technology for the delivery of targeted molecules also is generating considerable interest across the major companies, more so in the recent past.
- 5) No. of Investor complaints pending at the beginning of the quarter - NIL; received during the quarter - Nil; resolved during the quarter - NIL; pending unresolved at the end of the quarter - NIL.
- 6) The auditors have carried out a limited review of the above financial results and these were reviewed by the Audit committee and taken on record by the Board of Directors of the Company at their meeting held on 14-08-2014.
- 7) The company is in the process of getting residual value lives of various assets in order to switch to the new rates of depreciation as per schedule II - Depreciation under Companies Act 2013. As the company continues to apply old rates mentioned in Companies Act 1956 for current quarter also. Hence, the net impact between two rates cannot be quantified and reported.

Place: Hyderabad

Date : 14th August 2014

For and on behalf of the Board of Directors


Dr K Koteswara Rao

Chairman & Managing Director



Annexure IV to Clause 41
Reporting of Segment wise Revenue, Results and Capital Employed along with the quarterly results

(Rs. in Lakhs)

S.No	PARTICULARS	Quarter Ended 30.06.2014 (Unaudited)	Quarter Ended 31.03.2014 (Audited)	For the year ended 30.06.2013 (Unaudited)	Previous year Ended 31.03.2014 (Audited)
1	SEGMENT REVENUE	Rs.	Rs.	Rs.	Rs.
a)	Segment - A Diagnostic Services	10.52	12.99	10.88	48.42
b)	Segment - B Agri Division	0.00	0.00	0.00	0.00
c)	Segment - C Bulk Drugs Trading	0.00	0.00	0.00	0.00
d)	Segment - D CRO Services	0.00	15.26	0.00	27.26
e)	Segment - E API-DHA	0.00	0.00	13.01	22.43
Total:		10.52	28.25	23.89	98.11
	Less: Inter Segment Revenue				
	Net Sales/Income From Operation	10.52	28.25	23.89	98.11
2	SEGMENT RESULTS				
	(Profit/Loss Before Tax & Interest from each Segment)				
a)	Segment - A Diagnostic services	-0.05	1.16	0.42	4.40
b)	Segment - B Agri Division	0.00	0.00	0.00	0.00
c)	Segment - C Bulk Drugs Trading	0.00	0.00	0.00	0.00
d)	Segment - D CRO Services	0.00	5.11	0.00	13.46
e)	Segment - E API-DHA	-467.43	(1536.09)	(109.38)	(1879.02)
f)	R & D Expenses	(3.88)	(0.24)	(5.40)	(17.36)
	Total Segmental Result	(471.36)	(1530.05)	(114.36)	(1878.51)
	Other Income	0.00	(1490.05)	(114.36)	(1798.51)
Total		(471.36)			
	Less: Interest & Finance Charges	0.00	0.00	0.00	0.00
	Less: Intangible expenses	0.00	0.00	0.00	0.00
	Exceptional items-forex fluctuation gain/Loss	0.00	0	0.00	(0.00)
	Total Profit/Loss Before Tax	(471.36)	(1490.05)	(114.36)	(1798.51)
3	CAPITAL EMPLOYED				
a)	Segment - A Diagnostic services	324.83	324.83	324.83	324.83
b)	Segment - B Agri Division	24090.93	24090.93	24090.93	24090.93
c)	Segment - C Bulk Drugs				
Total		24415.76	24415.76	24415.76	24415.76

Place: Hyderabad
Date: 14-08-2014

For and on behalf of the Board of Directors

Dr. K. Kotamra Rao
Chairman & Managing Director



ANNEXURE IX TO CLAUSE 41

(Rs. In Laes)

Standalone Statement of Assets and Liabilities		As at year ended 31st March 2014	As at year ended 31st March 2013
		(Audited)	(Audited)
A EQUITY AND LIABILITIES			
1	Share Holders Fund		
	(a) Share Capital	7,577.00	7,577.00
	(b) Reserves and Surplus	23,669.46	24,045.64
	(c) Money Received against Share Warrants	-	-
	Sub Total - Share Holders' Fund	31,246.46	31,622.64
2	Share Application Money pending allotment	-	-
3	Minority Interest	-	-
4	Non-Current Liabilities		
	(a) Long Term Borrowings	593.21	593.21
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long-Term Liabilities	-	-
	(d) Long-term Provisions	565.72	565.72
	Sub-Total- Non Current Liabilities	1,158.93	1,158.94
5	Current Liabilities		
	(a) Short Term Borrowings	735.79	712.62
	(b) Trade Payables	1,709.53	1,708.37
	(c) Other Current Liabilities	119.32	124.86
	(d) Short-term Provisions	-	-
	Sub-Total- Current Liabilities	2,564.65	2,545.85
	TOTAL EQUITY AND LIABILITIES	34,970.04	35,327.42
B ASSETS			
1	Non-Current Assets		
	(a) Fixed Assets	17,658.35	18,087.37
	(b) Goodwill on Consolidation	-	-
	(c) Non- Current Investments	9,295.31	9,220.10
	(d) Deferred Tax Assets (Net)	-	-
	(e) Long-term Loans and Advances	2,819.48	2,799.51
	(f) Other Non Current Assets	3,198.85	3,198.85
	Sub - total -Non Current Assets	32,971.99	33,305.83
2	Current Assets		
	(a) Current Investments	-	-
	(b) Inventories	5.85	7.22
	(c) Trade Receivables	1,807.91	1,825.06
	(d) Cash and Cash Equivalents	3.90	5.17
	(e) Short-term Loans and Advances	180.38	184.14
	(f) Other Current Assets	-	-
	Sub-total- Current Assets	1,998.04	2,021.59
	TOTAL ASSETS	34,970.04	35,327.42

(0.00)

Place: Hyderabad
Date: 14-08-2014

For and on behalf of the Board of Directors

[Signature]
Dr K Koteswara Rao

Chairman & Managing Director





SARATH & ASSOCIATES

CHARTERED ACCOUNTANTS

LIMITED REVIEW REPORT

To
The Board of Directors
M/s Transgene Biotek Limited
Hyderabad

1. We have reviewed the accompanying statements of unaudited financial results of **M/s. Transgene Biotek Limited** for the quarter ended **30th June, 2014**, except for the disclosures regarding 'Public Shareholding' and 'Promoter Group Shareholding' and 'Number of Investor Complaints' which have been traced from disclosures made by the management but have not been audited by us. This statement has been prepared by the Company pursuant to clause 41 of the Listing Agreement with the Stock Exchange in India, which has been initialed by us for identification purpose. The Statement is the responsibility of the Company's Management and has been approved by the board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Financial Statements are free of Material Misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit Opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Un-audited Financial results for the Quarter ended 30th June, 2014 prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which is to be disclosed, *except the fact of providing Depreciation as per the rate prescribed in Companies Act, 1956 instead of new rates in accordance with Companies Act, 2013, the effect of which we are unable to arrive at the moment.*

Hyderabad
Date: 14th August, 2014

For Sarath & Associates
Chartered Accountants
Firm Regn. No. 005120S



[Signature]
P Sarath Kumar
Partner
M. No.021755

Head Office : 4th Floor, Maas Heights, 8-2-577/B, Road No.8, Banjara Hills, Hyderabad - 500 034.

Ph : Off : +91 40 23354322, 23357090, Fax : 23356716 ; e-mail : info@sarathcas.in, sarathcas@yahoo.com

MUMBAI : Indian Globe Chambers, 4th Floor, DN Road, Mumbai - 400 001, Ph : +91 22 22693132, Fax : +91 22 22621348, email: calakshmi.rao@gmail.com

VIZAG : 49-35-49, Srinivasam, Level-III, NGO'S Colony, Akkayyapalem, Visakhapatnam - 530016, Ph : 09550523111, Email : vdvsk@gmail.com